RARE-X logo

Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New Zealand

SAN DIEGO and ST GALLEN, Switzerland, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) and Vifor Pharma today announced the companies have entered into a joint collaboration and licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand. Sparsentan is a novel investigational product candidate currently being evaluated in pivotal Phase 3 clinical studies for the treatment of FSGS and IgAN, two rare progressive kidney disorders and leading causes of end-stage kidney disease. There are currently no approved medicines indicated for FSGS or IgAN. Sparsentan has been granted Orphan Drug Designation for the treatment of FSGS and IgAN in the U.S. and Europe.

Read the full press release >
RARE-X logo

Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of Directors

SAN DIEGO, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the appointment of Ruth Williams-Brinkley to the Company’s Board of Directors, effective immediately. Ms. Williams-Brinkley brings to Travere more than 35 years of executive leadership in care delivery and health plan operations.

Read the full press release >
RARE-X logo

Travere Announces Successful Outcome from Type A Meeting with U.S. FDA for Sparsentan in Focal Segmental Glomerulosclerosis

SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the Company’s plan to submit additional estimated glomerular filtration rate (eGFR) data from the ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) to support an application for accelerated approval in 2022.

Read the full press release >
RARE-X logo

Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, August 16, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced positive topline interim results from the ongoing pivotal Phase 3 PROTECT Study of sparsentan, an investigational product candidate for the treatment of IgA nephropathy (IgAN). The PROTECT Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than threefold reduction of proteinuria from baseline after 36 weeks of treatment, compared to the active control irbesartan (p<0.0001).

Read the full press release >
RARE-X logo

Travere Therapeutics Reports Second Quarter 2021 Financial Results

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2021 financial results and provided a corporate update.

Read the full press release >
Rare Revolution Magazine Summer 2021 Cover

Rare Revolution Magazine’s Releases Issue Focused on Diversity, Equity & Inclusion in Rare Disease

July 26, 2021 -- Today, Rare Revolution Magazine launched its summer issue dedicated to diversity, equity and inclusion in rare disease. The issue explores ways that rare disease patient advocacy organizations, individuals and industry are working to advance health equity. Articles include conversations with members of the rare community about race, gender, sexual identity, age bias, access to clinical trials and therapy. Travere is proud to collaborate with Rare Revolution Magazine on this issue. Read the issue >

Stuart

,
Ten years after being diagnosed with IgA nephropathy, a rare kidney disease, Stuart’s kidney function had depleted significantly. Today, after a lifesaving kidney donation from his wife, Stuart gives back to the kidney community through advocacy

In the News: Our president and CEO Eric Dube featured in Life Science Leader Magazine

July 1, 2021 -- In its July issue published today, Life Science Leader Magazine featured our president and CEO Eric Dube. The feature piece, “How a First-Time CEO Transformed Retrophin Into Travere Therapeutics”, highlights Eric’s inspirational leadership journey, why Eric decided to join the company, his first 100 days as a new CEO, and the company’s transition from Retrophin to Travere Therapeutics. Read the article >
RARE-X logo

Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021.

Read the full press release >
RARE-X logo

Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis

SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided a regulatory update for its sparsentan program in focal segmental glomerulosclerosis (FSGS).

Read the full press release >